Document is current

Article History

Received: 24 February 2020

Accepted: 8 June 2020

First Online: 14 June 2020

Compliance with ethical standards

:

: KO., M.P, and G.K. are employees and hold equity ownership in Bristol Myers Squibb. P.M.L. is advisory board member from AbbVie, GenMab, Genentech, CytomX, Takeda, Cybrexa, Agenus, IQVIA, TRIGR, Pfizer, I-MAB, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics; data safety monitoring board member from Agios, Five Prime, Halozyme, Tyme; member from imCORE Alliance (Roche-Genentech); and consultatnt of SOTIO. A.J.O. is advisory board member, with honoraria from: Array, BMS, Merck, Novartis and Pfizer. Trial funding (to institution) from: Adaptimmune; Alkermes; Astellas; BMS; Boston Biomedical; Checkmate Pharma; EMD Serono; Glenmark; Glyconex; GSK; Immunocore; Intensity Therapeutics; Kadmon; Kartos; Kura; Oncoceutics; OncoSec; Seattle Genetics; Sound Biologics; Spring Bank; Takeda; Targovax. O.R. does not have COI to disclose. C.X. and J.Y. are employees and hold equity ownership in Sanofi.

: The protocol and its amendments were submitted to local Ethics Committees, Institutional Review Boards for review and written approval. The protocol complied with recommendations of the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments with the laws and regulations, as well as any applicable guidelines of the United States, where the study was conducted. Informed consent was obtained at screening, prior to the conduct of any study-related procedures.